Variable | Univariate | Multivariate | |||
---|---|---|---|---|---|
Survivor (n = 89) | Non-survivor (n = 22) | P | OR (95% CI) | P | |
Male sex | 55 (61.8) | 16 (72.7) | 0.339 | 0.31 (0.06–1.75) | 0.186 |
Age, years | 78 (69.5–83.0) | 81.5 (74.3–86.3) | 0.064 | 1.07 (0.96–1.08) | 0.143 |
BMI, kg/m2 | 20.8 (18.7–23.7) | 18.3 (15.9–22.3) | 0.016 | 1.05 (0.85–1.31) | 0.643 |
APACHE II score | 25.0 (21.0–29.5) | 25.5 (22.0–30.3) | 0.459 |  |  |
Charlson Comorbidity Index | 2 (1–3) | 2 (1–3) | 1.000 |  |  |
Blood culture positive | 21 (23.6) | 4 (18.2) | 0.777 | Â | Â |
Permanent tracheostomy status | 26 (29.2) | 2 (9.1) | 0.052 | 0.35 (0.04–3.02) | 0.340 |
Nasogastric tube insertion status | 30 (33.7) | 8 (36.4) | 0.814 | Â | Â |
Invasive ventilation | 58 (65.2) | 19 (86.4) | 0.053 | 4.02 (0.68–23.76) | 0.124 |
ARDS | 21 (23.6) | 8 (36.4) | 0.222 | Â | Â |
Use of antibiotics within 3Â months | 37 (41.6) | 12 (54.5) | 0.273 | Â | Â |
MDR pathogen | 34 (38.2) | 19 (86.4) | < 0.001 | 17.43 (1.96–155.40) | 0.010 |
MRSA | 8 (9) | 10 (45.5) | < 0.001 |  |  |
CRAB | 16 (18) | 7 (31.8) | 0.238 | Â | Â |
Bedridden status | 44 (49.4) | 6 (27.3) | 0.061 | 0.24 (0.05–1.13) | 0.071 |
Brain problema | 69 (77.5) | 15 (68.2) | 0.36 | Â | Â |
Diabetes mellitus | 20 (22.5) | 7 (31.8) | 0.36 | Â | Â |
Hypertension | 37 (41.6) | 7 (31.8) | 0.402 | Â | Â |
Acute kidney injury | 27 (30.3) | 4 (18.2) | 0.255 | Â | Â |
Albumin, g/dL | 2.6 (2.3–2.9) | 2.0 (1.7–2.2) | < 0.001 |  |  |
Albumin < 2.15 g/dL | 13 (14.6) | 16 (72.7) | < 0.001 | 28.05 (5.47–143.75) | < 0.001 |
Total bilirubin, mg/dLb | 0.5 (0.3–0.8) | 0.6 (0.4–0.7) | 0.627 |  |  |
LDH, IU/L | 239 (185.5–307.5) | 258 (200.5–367.0) | 0.184 |  |  |
CRP, mg/dL | 13.0 (7.3–23.6) | 16.3 (12.8–21.3) | 0.151 |  |  |
NT-ProBNP pg/mL | 1337 (410–4462) | 2909.5 (1302.5–10,555.3) | 0.124 |  |  |
Triglyceride, mg/dLc | 76.0 (55.0–106.3) | 54.0 (43.0–83.0) | 0.034 |  |  |
ICU length of stay | 7 (3–14.5) | 5.5 (3.5–19) | 0.801 |  |  |